The global burden of psoriasis is rising.
Between 1990 and 2021, the estimated number of people living with psoriasis rose from 23.06 million to 42.98 million, an increase of 86%, while annual new cases increased from 2.85 million to 5.10 million. A growing and aging population explains some of that increase, but not all of it: the age-standardized prevalence rate rose from 477.7 to 516.0 cases per 100,000 people, while the age-standardized incidence rate increased from 57.0 to 62.0 cases per 100,000. A separate analysis of the same global disease-burden data similarly found that the number of people living with psoriasis nearly doubled over those three decades and projected that the burden will continue to rise as populations grow and age.
The increase has not been uniform. Epidemiological trends differ among countries, and changes in recognition, diagnosis, healthcare access, and population structure can influence the number of cases being recorded. But those qualifications do not erase the broader pattern: more people are living with a chronic inflammatory disease that is still routinely treated as though it begins and ends at the surface of the skin.
Psoriasis is easy to reduce to what can be seen: thick plaques, persistent scale, itching, cracking, and skin that may clear for a time only to flare again. Yet the visible lesion is only the place where the disease announces itself. Psoriasis is a chronic, immune-mediated inflammatory disease that can affect physical comfort, sleep, psychological well-being, work, relationships, and social life, while also being associated with psoriatic arthritis, cardiovascular disease, metabolic disorders, inflammatory bowel disease, and depression.
The skin makes that burden unusually public. High blood pressure, altered blood glucose, and circulating inflammatory markers can remain hidden from casual view, but plaques on the scalp, face, hands, elbows, or legs may be difficult to conceal. The effects on daily life do not always correspond neatly to the percentage of skin involved, because a smaller lesion on the face, hands, genitals, or scalp can carry a physical and psychological burden disproportionate to its size. Psoriasis is therefore both more visible than many chronic diseases and more biologically complex than its appearance suggests.
Psoriasis is often explained as skin cells growing too quickly, but accelerated growth is the result, not the full disease. Psoriatic inflammation develops through sustained communication among dendritic cells, T cells, neutrophils, macrophages, inflammatory cytokines, and keratinocytes, the predominant cells of the epidermis. The IL-23–IL-17 pathway is central to this response: immune-derived signals activate keratinocytes and accelerate their proliferation, while activated keratinocytes release cytokines, chemokines, antimicrobial peptides, and cellular danger signals that recruit and stimulate more immune cells. A plaque is not simply a pileup of excess skin. It is the visible product of a feedback loop in which immune activation and abnormal keratinocyte behavior continually reactivate one another.
Oxidative stress sits inside that loop. Reactive oxygen species (ROS) are normal participants in cellular signaling, metabolism, and immune defense, but oxidative stress develops when their production exceeds the capacity of antioxidant and repair systems to keep cellular damage under control. Systematic reviews have found elevated markers of oxidative damage and altered antioxidant activity in people with psoriasis, with greater redox imbalance often associated with longer disease duration, inflammatory activity, and more severe skin involvement.
Excessive reactive species can damage cellular lipids, proteins, and DNA while activating redox-sensitive inflammatory pathways and interfering with normal epidermal differentiation and barrier function. At the same time, activated immune cells and metabolically stressed keratinocytes can generate additional oxidative pressure, allowing inflammation and redox imbalance to reinforce one another. Inflammation produces oxidative stress. Oxidative stress amplifies inflammatory signaling. Both help maintain the cellular conditions in which keratinocytes continue to proliferate and inflamed skin struggles to return to normal regulation.
This feedback does not necessarily remain confined to the plaque. Psoriatic inflammation is associated with joint disease, obesity, insulin resistance, dyslipidemia, cardiovascular disease, inflammatory bowel disease, and psychiatric disorders, although the risk and strength of these associations vary with disease severity, age, genetics, behavior, treatment, and other health factors. Psoriasis is not the product of one malfunctioning pathway. It reflects dysregulated communication among the immune system, skin barrier, cellular metabolism, redox balance, and the mechanisms that would normally resolve inflammation and restore tissue stability.
Modern treatments have transformed what is possible. Topical corticosteroids and vitamin D analogues remain important for localized disease, while phototherapy, oral systemic medicines, and biologics targeting TNF, IL-17, IL-23, and related pathways can produce substantial improvement in moderate-to-severe psoriasis. Their effectiveness also confirms how central inflammatory cytokines are to the disease. Yet psoriasis remains chronic and prone to recurrence, and long-term management may involve repeated topical treatment, injections, laboratory monitoring, medication changes, adverse effects, loss of treatment response, or combinations of therapies. Clearing the skin is increasingly possible. Keeping the disease controlled over time can be more complicated.
That gap between suppressing a flare and changing the biological conditions that sustain it is where molecular hydrogen (H₂) becomes relevant. This gas molecule is often described simply as an antioxidant, but the emerging psoriasis research places it within a broader set of processes involving redox regulation, inflammatory cytokine production, immune-cell behavior, keratinocyte proliferation, cellular metabolism, and localized delivery into inflamed skin. Its potential relevance is therefore not that it targets one psoriasis pathway more aggressively, but that it may influence several interacting parts of the inflammatory loop at once.
The human evidence is limited but encouraging. In a parallel-controlled study, 41 patients added hydrogen-water bathing to their existing psoriasis treatment while 34 patients continued conventional treatment with ordinary bathing. After eight weeks, 56.1% of the hydrogen-bathing group had achieved at least a 50% reduction in Psoriasis Area and Severity Index scores, compared with 17.7% of controls, while 24.4% achieved at least a 75% reduction, compared with 2.9% of controls. Itching also improved, although the study was not a large randomized, placebo-controlled clinical trial and the participants continued their existing therapies. An earlier report described improvements in skin lesions, psoriatic arthritis activity, and selected inflammatory or oxidative-stress markers in three patients receiving different forms of molecular hydrogen, although the absence of a control group makes those cases preliminary rather than confirmatory evidence.
Subsequent cell and animal studies have made the biological question more specific. Hydrogen-rich bathing reduced psoriasis-like skin changes, IL-17, IL-23, TNF-α, lipid peroxidation, immune-cell activity, and keratinocyte proliferation in an imiquimod-induced mouse model. Hydrogen-rich water has also been studied in dyslipidemic mice with psoriasis-like inflammation, where it affected skin pathology, inflammatory signaling, lipid metabolism, and the balance between pro-inflammatory and inflammation-resolving macrophage phenotypes. More recent work found that hydrogen suppressed psoriasis-like inflammation by inhibiting cGAS–STING signaling, reducing reactive oxygen species and inflammatory cytokines, and limiting abnormal keratinocyte proliferation in cellular and animal models. Together, these findings place H2 across several parts of the same disease network: oxidative stress, innate immune activation, cytokine signaling, macrophage behavior, and epidermal overgrowth.
The skin may also offer a route for delivering hydrogen directly where the inflammatory cycle is occurring. Experimental magnesium-hydride microneedles have been designed to generate hydrogen within psoriatic skin over an extended period, reducing oxidative damage, inflammatory cytokines, immune-cell infiltration, and keratinocyte hyperproliferation in preclinical models. A sustained hydrogen-generating hydrogel has similarly been used to influence PKM2-associated, Warburg-like energy metabolism in psoriatic keratinocytes while restoring redox balance and disrupting inflammatory feedback in cell and mouse experiments. These delivery systems raise the possibility that hydrogen could eventually be generated locally and continuously within inflamed tissue, where its concentration and duration of exposure may be easier to control.
None of this establishes molecular hydrogen as a replacement for dermatological care, topical medication, systemic treatment, or biologic therapy. The clinical evidence remains limited, while the most detailed findings involving immune pathways, cellular metabolism, microneedles, hydrogels, and relapse prevention still come from cells and animals. Nor is it yet clear which delivery method, dose, treatment duration, or patient population would be most likely to benefit.
The value of the research lies in the question it opens. Psoriasis treatment has largely focused on suppressing the inflammatory signals that produce plaques. Molecular hydrogen is being studied for whether it can also influence the redox, metabolic, immune, and cellular conditions that allow those signals to persist, interact, and restart the inflammatory cycle.
Psoriasis may appear on the surface, but it persists through biology beneath it. Clearing a plaque addresses what the disease has produced. The deeper challenge is interrupting the system that allows the plaque to form, persist, and return.
References
· Armstrong, A.W., Blauvelt, A., Callis Duffin, K. et al. Psoriasis. Nat Rev Dis Primers 11, 45 (2025). https://doi.org/10.1038/s41572-025-00630-5
· Armstrong, A. W., & Read, C. (2020). Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA, 323(19), 1945–1960. https://doi.org/10.1001/jama.2020.4006
· Cannavò, S. P., Riso, G., Casciaro, M., Di Salvo, E., & Gangemi, S. (2019). Oxidative stress involvement in psoriasis: a systematic review. Free radical research, 53(8), 829–840. https://doi.org/10.1080/10715762.2019.1648800
· Dobrică, E. C., Cozma, M. A., Găman, M. A., Voiculescu, V. M., & Găman, A. M. (2022). The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants (Basel, Switzerland), 11(2), 282. https://doi.org/10.3390/antiox11020282
· Ishibashi, T., Ichikawa, M., Sato, B., Shibata, S., Hara, Y., Naritomi, Y., Okazaki, K., Nakashima, Y., Iwamoto, Y., Koyanagi, S., Hara, H., & Nagao, T. (2015). Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases. Molecular medicine reports, 12(2), 2757–2764. https://doi.org/10.3892/mmr.2015.3707
· Jin, J., Yue, L., Du, M., Geng, F., Gao, X., Zhou, Y., Lu, Q., & Pan, X. (2025). Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application. MedComm, 6(5), e70194. https://doi.org/10.1002/mco2.70194
· Lin, L., Guan, Q., Ding, Z., Zou, J., Dong, C., Zhu, X., Fan, W., Li, H., Xu, J., Tan, J., Ding, W., Pei, J., & Du, J. (2026). Reshaping psoriasis topical therapy: Continuous hydrogenation orchestrates 'redox-metabolic homeostasis' for efficient remission and relapse intervention. Bioactive materials, 62, 686–701. https://doi.org/10.1016/j.bioactmat.2026.03.018
· Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual review of immunology, 32, 227–255. https://doi.org/10.1146/annurev-immunol-032713-120225
· Ma, F., Plazyo, O., Billi, A. C., Tsoi, L. C., Xing, X., Wasikowski, R., Gharaee-Kermani, M., Hile, G., Jiang, Y., Harms, P. W., Xing, E., Kirma, J., Xi, J., Hsu, J. E., Sarkar, M. K., Chung, Y., Di Domizio, J., Gilliet, M., Ward, N. L., Maverakis, E., … Gudjonsson, J. E. (2023). Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis. Nature communications, 14(1), 3455. https://doi.org/10.1038/s41467-023-39020-4
· Qiu, Z., Huang, A., Li, Z., Qin, S., Chen, J., Li, B., Liu, B., & He, L. (2025). Hydrogen-rich water ameliorates imiquimod-induced psoriasis-like skin lesions and regulates macrophage polarization in dyslipidemic ApoE-deficient mice. European journal of pharmacology, 992, 177363. https://doi.org/10.1016/j.ejphar.2025.177363
· Wei, J., Wang, Y., Chen, Y., Wang, Z., Dai, X., Gelfand, J. M., Bachelez, H., Chen, X., Xiao, Y., & Shen, M. (2026). Global Burden of Psoriasis from 1990 to 2021 and Potential Factors: A Systematic Analysis. The Journal of investigative dermatology, 146(4), 1034–1045.e22. https://doi.org/10.1016/j.jid.2025.08.038
· Wu, Y., Wang, X., Sun, Y., Duan, Y., Zhang, M., Sang, H., Yu, P., & Kong, Q. (2026). Hydrogen ameliorates psoriasis-like skin inflammation via inhibiting the cGAS-STING pathway. Clinical and experimental immunology, 220(1), uxaf081. https://doi.org/10.1093/cei/uxaf081
· Xiong, J., Xue, T., Tong, M., Xu, L., & Bai, B. (2025). Dynamic trend analysis of global psoriasis burden from 1990 to 2021: a study of gender, age, and regional differences based on GBD 2021 data. Frontiers in public health, 13, 1518681. https://doi.org/10.3389/fpubh.2025.1518681
· Zhang, X., Yu, P., Hong, N., Liu, F., Shan, Y., Wu, Y., An, B., Sang, H., & Kong, Q. (2023). Effect and mechanism of hydrogen-rich bath on mice with imiquimod-induced psoriasis. Experimental dermatology, 32(10), 1674–1681. https://doi.org/10.1111/exd.14872
· Zhu, D. D., Lim, R. Y. D., Poh, Y. L., Li, D. S., Raghavan, S., & Chen, P. (2025). Transdermal hydrogen therapy for psoriasis using cavity-embedded double-conical microneedles. Journal of controlled release : official journal of the Controlled Release Society, 388(Pt 1), 114313. https://doi.org/10.1016/j.jconrel.2025.114313
· Zhu, Q., Wu, Y., Li, Y., Chen, Z., Wang, L., Xiong, H., Dai, E., Wu, J., Fan, B., Ping, L., & Luo, X. (2018). Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. Scientific reports, 8(1), 8051. https://doi.org/10.1038/s41598-018-26388-3
